Change in the shareholding structure of SEQENS – SEQENS is now stronger, more focused and positioned as one of the main global players in pharmaceutical solutions and specialty ingredients

ECULLY, France Р(COMMERCIAL THREAD) РSEQENS is pleased to announce that, on December 16, 2021, the funds advised by SK Capital became the majority shareholder of the group. Two new long-term institutional investors, Bpifrance and Nov Sant̩, are participating in the transaction alongside SK Capital, management and historic minority shareholders M̩rieux Equity Partners, Ardian and Eximium, who are reinvesting in SEQENS.

Along with this investment, SEQENS has partnered with Wavelength Pharmaceuticals, an API development and manufacturing company and an existing SK Capital holding company. SEQENS also sold its non-strategic Mineral Specialties activities, namely the sodium bicarbonate, sodium carbonate and sodium silicate production plants at Laneuveville-devant-Nancy (France), Nogent l’Artaud (France) and Jurong Island (Singapore), all of which will remain under the control of Eurazeo and the other historic shareholders of SEQENS.

Thanks to these operations, SEQENS is now emerging stronger and more concentrated, positioned as one of the main global players in pharmaceutical solutions and specialty ingredients, with a turnover of 1.1 billion euros, 24 industrial sites , 10 R&D centers and 3,200 employees located on 3 continents. The company has an extensive product portfolio of more than 200 active pharmaceutical ingredients, 500 pharmaceutical intermediates, as well as specialty ingredients and key chemicals. SEQENS invests significantly to support the growth of its customers in its commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, high power APIs and biocatalysis. The company is committed to meeting the highest levels of environmental, social and governance standards, with 15 Platinum and Gold EcoVadis sites across its global network.

“We are very pleased to have the opportunity to support SEQENS with our experience and extensive relationships in the pharmaceutical and specialty ingredient markets. SEQENS is renowned for its recognized know-how, its capacity for innovation, its global industrial footprint and its broad portfolio of products and technologies. The combination with Wavelength further expands these strengths for the benefit of our customers and collective employees. We are delighted with the continued commitment of its current shareholders, Mérieux Equity Partners, Ardian and Eximium as well as the new shareholders Bpifrance and Nov Santé, who will offer the company a wide range of perspectives and capital to continue its growth,said Aaron Davenport, Managing Director of SK Capital.

“With the support of its shareholders, the group has become one of the world leaders in pharmaceutical synthesis. The significant investments made over the past five years in our factories, in R&D and in disruptive technologies allow us to offer the widest range of services and products on the market for the benefit of our customers. With SK Capital, supported by Bpifrance, Nov Santé, Mérieux, Ardian and Eximium and with the combination of technologies, capacities, products and recognized know-how of Wavelength, we will accelerate the projects launched in recent months and further strengthen our positions to support our customers around the world in the development of their projects ”, declared Pierre Luzeau, President of SEQENS.

José Gonzalo, Executive Director of Direct Investments at Bpifrance, added: “Bpifrance is proud to support the SEQENS management team in its ambitious investment program for growth. SEQENS is a French industrial success story and a leading force in the pharmaceutical and specialty ingredients industries, with a strong footprint in France. Our investment is a demonstration of Bpifrance’s commitment to support this strategic sector.


SEQENS is a world leader in the development and production of active ingredients, pharmaceutical intermediates and specialty ingredients by relying on 24 manufacturing sites, 10 R&D centers and 3,200 employees spread over 3 continents.

An integrated player across the entire value chain – from raw materials to active ingredients and from research and development to industrialization – SEQENS offers a large portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients and chemicals, develops and industrializes them. most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies.

Driven by a culture of excellence and a strong entrepreneurial spirit, our employees are committed to providing our customers with the highest level of service and quality while acting ethically in accordance with our strong environmental, social and management program. governance.

[email protected] / / Linkedin: SEQENS / Twitter: @seqens_group


SK Capital is a private investment firm specializing in the specialty materials, chemicals and pharmaceuticals industries. The company seeks to build strong, growing businesses that create substantial long-term value. SK Capital aims to use its industry, operations and investment experience to identify opportunities to transform businesses into better performing organizations with strategic positioning, improved growth and profitability as well as lower operational risk. . SK Capital’s business portfolio generates approximately $ 13 billion annually, employs more than 18,000 people worldwide and operates 170 factories in 32 countries.

For more information, visit

About Bpifrance:

Bpifrance is the French national investment bank: it finances companies – at all stages of their development – through loans, guarantees, equity investments and export insurance. Bpifrance also offers additional financial services (training, advice) to help entrepreneurs meet their challenges (innovation, export, etc.).

For more information: – – Follow us on Twitter: @Bpifrance @BpifrancePresse

Press contact: [email protected]

About Dianne Stinson

Check Also

10 Xbox Games That Aren’t As Good As You Remember

Building on the experience they had gained through their collaborations with companies such as Sega, …